-
Article
Open AccessOncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients
Nowadays, evaluation of the efficacy and the duration of treatment, in context of monitoring patients with solid tumors, is based on the RECIST methodology. With these criteria, resistance and/or insensitivity...
-
Article
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort
Docetaxel–cisplatin-5-FU chemotherapy is superior to 5-FU-cisplatin in terms of response rate and survival in advanced gastric cancer (AGC), but is more toxic. Oxaliplatin is better tolerated than cisplatin, w...
-
Book
-
Chapter
Traitement des cancers digestifs du sujet âgé
Les cancers digestifs surviennent dans la grande majorité des cas chez les patients âgés de plus de 65 ans. Compte tenu du vieillissement de la population, l’incidence des cancers digestifs chez les sujets âgé...
-
Article
Open AccessBevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal...
-
Chapter
Traitement des cancers digestifs du sujet âgé
Les cancers digestifs surviennent dans la grande majorité des cas chez les patients âgés de plus de 65 ans. Compte tenu du vieillissement de la population, l’incidence des cancers digestifs chez les sujets âgé...
-
Book
Les cancers digestifs
Avec la collaboration de l’Association des Gastro-entérologues Oncologues (AGEO)